Protective effects of MCI-186 on oxidative damage in a cell model of Alzheimer's disease

Neural Regeneration Research

Volumn 5, Issue 16, 2010, Pages 1226-1230

  Yu, Ming ^a   Li, Shujuan ^a   Leng, Wenhui ^a   Chen, Han ^a   Wu, Yingquan ^a   Yan, Lirong ^a  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Beta amyloid protein 25 35; MCI 186 (edaravone); Neural regeneration; Neurodegenerative diseases; Oxidative stress damage; Pheochromocytoma (PC12) cells

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN[25-35]; CARBONYL DERIVATIVE; DNA; HYDROXYL RADICAL; MALONALDEHYDE; NORPHENAZONE;

ALZHEIMER DISEASE; ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL SURVIVAL; COMET ASSAY; CONTROLLED STUDY; DISEASE MODEL; DNA DAMAGE; DRUG EFFECT; DRUG MECHANISM; IN VITRO STUDY; LIPID OXIDATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHEOCHROMOCYTOMA CELL; PROTEIN SYNTHESIS INHIBITION; RAT; SURVIVAL RATE;

EID: 77958017758     PISSN: 16735374     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2010.16.005     Document Type: Article

References (27)

1. Sugimoto H. The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis. Chem Biol Interact. 2008;175(1-3):204-208.
2. Sapra M, Kim KY. Anti-amyloid treatments in Alzheimer's disease. Recent Pat CNS Drug Discov. 2009;4(2):143-148.
3. Maccioni RB, Rojo LE, Fernández JA, et al. The role of neuroimmunomodulation in Alzheimer's disease. Ann N Y Acad Sci. 2009;1153:240-246.
4. Praticò D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann N Y Acad Sci. 2008;1147:70-78.
5. Koudinov A, Kezlya E, Koudinova N, et al. Amyloid-beta, tau protein, and oxidative changes as a physiological compensatory mechanism to maintain CNS plasticity under Alzheimer's disease and other neurodegenerative conditions. J Alzheimers Dis. 2009; 18(2):381-400.
6. Kadenbach B, Ramzan R, Vogt S. Degenerative diseases, oxidative stress and cytochromec oxidase function. Trends Mol Med. 2009;15(4):139-147.
7. Zhu X, Smith MA, Honda K, et al. Vascular oxidative stress in Alzheimer disease. J Neurol Sci. 2007;257(1-2):240-246.
8. Kanski J, Varadarajan S, Aksenova M, et al. Role of glycine-33 and methionine-35 in Alzheimer's amyloid beta-peptide1-42- associated oxidative stress and neurotoxicity. Biochim Biophys Acta. 2002;1586(2):190-198.
9. Brinton RD. Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease. Adv Drug Deliv Rev. 2008;60(13-14): 1504-1511.
10. Olcese JM, Cao C, Mori T, et al. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res. 2009;47(1):82-96.
11. Qiu W, Gu H, Zheng L, et al. Pretreatment with edaravone reduces lung mitochondrial damage in an infant rabbit ischemia-reperfusion model. J Pediatr Surg. 2008;43(11): 2053-2060.
12. Ohta Y, Takamatsu K, Fukushima T, et al. Efficacy of the free radical scavenger, edaravone, for motor palsy of acute lacunar infarction. Intern Med. 2009;48(8):593-596.
13. Nakamura T, Kuroda Y, Yamashita S, et al. Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage. Stroke. 2008;39(2):463-469.
14. Munakata A, Ohkuma H, Nakano T, et al. Effect of a free radical scavenger, edaravone, in the treatment of patients with aneurysmal subarachnoid hemorrhage. Neurosurgery. 2009; 64(3):423-428.
15. Yu M, Zhang XL, Leng WH, et al. Neuroprotective effects of MCI-186 on the PC12 cells induced by Aß25-35. Jiangsu Yiyao. 2009;35(11):1317-1320.
16. Balu M, Sangeetha P, Murali G, et al. Age-related oxidative protein damages in central nervous system of rats: modulatory role of grape seed extract. Int J Dev Neurosci. 2005;23(6):501-507.
17. Takeuchi M, Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des. 2008;14(10):973-978.
18. Leclerc E, Sturchler E, Vetter SW, et al. Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer's disease. Rev Neurosci. 2009;20(2): 95-110.
19. Mohmmad Abdul H, Sultana R, Keller JN, et al. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease. J Neurochem. 2006;96(5):1322-1335.
20. Zhang P, Dilley C, Mattson MP. DNA damage responses in neural cells: Focus on the telomere. Neuroscience. 2007;145(4): 1439-1448.
21. Liu CY, Lee CF, Wei YH. Role of reactive oxygen species-elicited apoptosis in the pathophysiology of mitochondrial and neurodegenerative diseases associated with mitochondrial DNA mutations. J Formos Med Assoc. 2009;108(8):599-611.
22. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443(7113):787-795.
23. Best BP. Nuclear DNA damage as a direct cause of aging. Rejuvenation Res. 2009;12(3):199-208.
24. Alamdari DH, Kostidou E, Paletas K, et al. High sensitivity enzyme-linked immunosorbent assay (ELISA) method for measuring protein carbonyl in samples with low amounts of protein. Free Radic Biol Med. 2005;39(10):1362-1367.
25. Hou FF, Chertow GM, Kay J, et al. The interaction between beta 2-microglobulin end advanced glycation and products in the development of dialysis related-amyloidosis. Kidney Int. 1997; 51(5):1514-1519.
26. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95(2): 351-358.
27. Singh NP, McCoy MT, Tice RR, et al. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988;175(1):184-191.